6-Gingerol Protects against Nutritional Steatohepatitis by Regulating Key Genes Related to Inflammation and Lipid Metabolism

Non-alcoholic fatty liver disease, including non-alcoholic steatohepatitis (NASH), appears to be increasingly common worldwide. The aim of the study was to investigate the effects of 6-gingerol ((S)-5-hydroxy-1-(4-hydroxy-3-methoxyphenyl)-3-decanone), a bioactive ingredient of plants belonging to the Zingiberaceae family, on experimental models of NASH. In HepG2 cells, 6-gingerol (100 μmol/L) treatment inhibited free fatty acids mixture (0.33 mmol/L palmitate and 0.66 mmol/L oleate)-induced triglyceride and inflammatory marker accumulations. Male C57BL/6 mice were fed with a methionine and choline-deficient (MCD) diet to induce steatohepatitis. After four weeks of MCD diet feeding, the mice were dosed orally with 6-gingerol (25, 50 or 100 mg/kg/day) once daily for another four weeks. 6-Gingerol (100 mg/kg/day) attenuated liver steatosis and necro-inflammation in MCD diet-fed mice. The expressions of inflammatory cytokine genes, including those for monocyte chemoattractant protein-1, tumor necrosis factor-α, and interleukin-6, and nuclear transcription factor (NF-κB), which were increased in the livers of MCD diet-fed mice, were attenuated by 6-gingerol. 6-Gingerol possesses a repressive property on hepatic steatosis, which is associated with induction of peroxisome proliferator-activated receptor α. Our study demonstrated the protective role of 6-gingerol in ameliorating nutritional steatohepatitis. The effect was mediated through regulating key genes related to lipid metabolism and inflammation.

[1]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[2]  F. Gonzalez,et al.  Role of white adipose lipolysis in the development of NASH induced by methionine- and choline-deficient diet. , 2014, Biochimica et biophysica acta.

[3]  Jung-Chun Liao,et al.  Analgesic and anti-inflammatory activities of [6]-gingerol. , 2005, Journal of ethnopharmacology.

[4]  M. Sherman,et al.  Nutritional assessment and hepatic fatty acid composition in non-alcoholic fatty liver disease (NAFLD): a cross-sectional study. , 2008, Journal of hepatology.

[5]  E. Zandi,et al.  A cytokine-responsive IkappaB kinase that activates the transcription factor NF-kappaB. , 1997, Nature.

[6]  W. Chang,et al.  Inhibitory effects of phenolics on xanthine oxidase. , 1994, Anticancer research.

[7]  S. Kersten,et al.  Peroxisome proliferator-activated receptor α target genes , 2004, Cellular and Molecular Life Sciences CMLS.

[8]  I. Leclercq,et al.  Administration of the potent PPARα agonist, Wy‐14,643, reverses nutritional fibrosis and steatohepatitis in mice , 2004, Hepatology.

[9]  A. Koteish,et al.  Animal models of steatohepatitis. , 2002, Best practice & research. Clinical gastroenterology.

[10]  O. Cummings,et al.  Design and validation of a histological scoring system for nonalcoholic fatty liver disease , 2005, Hepatology.

[11]  K. Tsuneyama,et al.  Hepatoprotective effect of tamoxifen on steatosis and non-alcoholic steatohepatitis in mouse models. , 2012, The Journal of toxicological sciences.

[12]  M. Goldring,et al.  NF-kappaB signaling: multiple angles to target OA. , 2010, Current drug targets.

[13]  H. Kwan,et al.  Inhibition of DNA-dependent protein kinase reduced palmitate and oleate-induced lipid accumulation in HepG2 cells , 2013, European Journal of Nutrition.

[14]  J. Jessurun,et al.  Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. , 2005, The Journal of clinical investigation.

[15]  D. Lawlor,et al.  Prevalence of elevated alanine aminotransferase among US adolescents and associated factors: NHANES 1999-2004. , 2007, Gastroenterology.

[16]  K. Ogawa,et al.  Morphological and functional characterization of non-alcoholic fatty liver disease induced by a methionine-choline-deficient diet in C57BL/6 mice. , 2013, International journal of clinical and experimental pathology.

[17]  M. Nyirenda,et al.  Metabolic pathways promoting intrahepatic fatty acid accumulation in methionine and choline deficiency: implications for the pathogenesis of steatohepatitis , 2010, American journal of physiology. Endocrinology and metabolism.

[18]  G. Farrell,et al.  Nonalcoholic fatty liver disease: From steatosis to cirrhosis , 2006, Hepatology.

[19]  Michael Müller,et al.  Peroxisome Proliferator-Activated Receptor Alpha Target Genes , 2010, PPAR research.

[20]  M. Hesselink,et al.  Optimisation of oil red O staining permits combination with immunofluorescence and automated quantification of lipids , 2001, Histochemistry and Cell Biology.

[21]  A. Lombardi,et al.  From chronic overnutrition to insulin resistance: the role of fat-storing capacity and inflammation. , 2009, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[22]  R. Harmon,et al.  Inflammation in nonalcoholic steatohepatitis , 2011, Expert review of gastroenterology & hepatology.

[23]  C. Teng,et al.  Antiplatelet Effect of Gingerol Isolated from Zingiber officinale , 1995, The Journal of pharmacy and pharmacology.

[24]  B. Neuschwander‐Tetri,et al.  Nonalcoholic steatohepatitis: Summary of an AASLD Single Topic Conference , 2003, Hepatology.

[25]  J. Folch,et al.  A simple method for the isolation and purification of total lipides from animal tissues. , 1957, The Journal of biological chemistry.

[26]  Xiao-Hong Li,et al.  Attenuation of Proinflammatory Responses by S-[6]-Gingerol via Inhibition of ROS/NF-Kappa B/COX2 Activation in HuH7 Cells , 2013, Evidence-based complementary and alternative medicine : eCAM.

[27]  M. Duvnjak,et al.  Pathogenesis and management issues for non-alcoholic fatty liver disease. , 2007, World journal of gastroenterology.

[28]  J. Corton,et al.  Central role of peroxisome proliferator-activated receptors in the actions of peroxisome proliferators. , 2000, Annual review of pharmacology and toxicology.

[29]  Y. Surh,et al.  [6]-Gingerol prevents UVB-induced ROS production and COX-2 expression in vitro and in vivo , 2007, Free radical research.

[30]  F. Gonzalez,et al.  PPARalpha expression protects male mice from high fat-induced nonalcoholic fatty liver. , 2011, The Journal of nutrition.

[31]  C. Day,et al.  Steatohepatitis: a tale of two "hits"? , 1998, Gastroenterology.

[32]  J. Tieppo,et al.  Methionine- and choline-deficient diet induces hepatic changes characteristic of non-alcoholic steatohepatitis. , 2011, Arquivos de gastroenterologia.

[33]  N. Lalwani,et al.  Induction of hepatic peroxisome proliferation in nonrodent species, including primates. , 1984, The American journal of pathology.

[34]  Jianghua Chen,et al.  Rhabdomyolysis associated with fibrate therapy: review of 76 published cases and a new case report , 2009, European Journal of Clinical Pharmacology.

[35]  A. Casquero,et al.  Ciprofibrate increases cholesteryl ester transfer protein gene expression and the indirect reverse cholesterol transport to the liver , 2009, Lipids in Health and Disease.

[36]  David M. Rothwarf,et al.  A cytokine-responsive IκB kinase that activates the transcription factor NF-κB , 1997, Nature.

[37]  D. Vance,et al.  Nascent VLDL phospholipid composition is altered when phosphatidylcholine biosynthesis is inhibited: evidence for a novel mechanism that regulates VLDL secretion. , 1995, Biochimica et biophysica acta.

[38]  Robert V Farese,et al.  Lipopenia and Skin Barrier Abnormalities in DGAT2-deficient Mice* , 2004, Journal of Biological Chemistry.

[39]  Nilendra Singh,et al.  Anti-hyperglycaemic, lipid lowering and anti-oxidant properties of (6)-gingerol in db/db mice , 2009 .

[40]  M. Goldring,et al.  NF-kappaB signaling: multiple angles to target OA. , 2010, Current drug targets.